AstridBio Technologies

Medical, Industry Outlook

PRNewswire | July 14, 2023

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge antibody technology innovation and provider of integrated solutions from "Idea to IND" (I to ITM) announced that, DualityBio, a collaborator of Nona Biosciences, and BeiGene entered into an agreement for BeiGene to acquire an exclusive option for a global clinical and commercial license to an investigational, preclinical ADC program for patients with select solid tumors. This program wa...

MedTech

Ginkgo Bioworks | August 20, 2022

Ginkgo Bioworks the leading horizontal platform for cell programming, announced the purchase of certain epidemiological data infrastructure assets from Baktus, Inc., a Delaware-based public benefit corporation. Under the terms of the deal, Ginkgo will assume ownership of proprietary datasets, modeling and analytic tools, and a software platform with the capabilities to track, model, and forecast epidemics and associated risks and impacts. Ginkgo also expects to integrate several ongoing epidemio...

Medical

Vibe Bio | June 23, 2022

Vibe Biotechnology Inc., a biotechnology company committed to identifying, funding, and developing promising treatments for rare diseases, announced officially launching with $12 million in funding to advance its community-driven approach to transforming drug development for patients with rare diseases. Vibe Bio plans on building a global community of scientists, researchers, patients, and partners with an aim to find cures for rare diseases by efficiently using a decentralized au...

Cell and Gene Therapy

Mekonos, Inc. | November 10, 2021

Mekonos, a biotech company building the future of cell therapies on a chip, has raised $25M in an oversubscribed Series A round co-led by Reimagined Ventures, Fiscus Ventures, and PEAK6 Strategic Capital, a division of PEAK6 Investments. New institutional and strategic investors, including Section 32, Sands Capital, TDK Ventures, and the venture arm of Debiopharm, and previous investors, including Novartis Pharma AG (dRx Capital) and Elementum Ventures, also joined in the funding round that will...